This study is currently not recruiting participants.
A Multicenter Open-Label Study to Assess the Pharmacokinetics Safety and Efficacy of Certolizumab Pegol in Children and Adolescents with Moderately to Severely Active Polyarticular-Course Juvenile Idiopathic Arthritis
Not Recruiting
2 years - 17 years
All
Phase
N/A
1 Location
Brief description of study.
The purpose of this clinical research study is to assess the pharmacokinetics (blood concentration of the study medication during and after treatment) and the safety of CZP (Cimzia) in children and adolescents with JIA.
Detailed description of study
The purpose of this clinical research study is to assess the pharmacokinetics (blood concentration of the study medication during and after treatment) and the safety of CZP (Cimzia) in children and adolescents with JIA.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: Juvenile Idiopathic Arthritis
-
Age: 2 years - 17 years
-
Gender: All
Updated on
23 Apr 2012.
Study ID: 1201007800
Interested in the study?
Select a study center that’s convenient for you, and get in touch with the study team.
Please choose between Voice or SMS based delivery of verification code
or